In­cyte ax­es JAK1 in­hibitor from pipeline two years af­ter a PhI­II flop crushed hopes

In the first few days of 2020, In­cyte re­port­ed that its JAK1 in­hibitor failed a Phase III study in first-line, acute graft vs host dis­ease. With the flop came a $2 bil­lion mar­ket cap era­sure.

This time around, In­cyte isn’t even com­plet­ing a study of the drug, known as itac­i­tinib, be­cause ef­fi­ca­cy da­ta from part of a Phase II/III study give the bio­phar­ma no signs of hope for a piv­otal suc­cess.

The GRAV­I­TAS-309 study was test­ing itac­i­tinib in pa­tients with treat­ment-naïve chron­ic GVHD, but the com­pa­ny de­cid­ed to scrap those plans, it re­vealed Tues­day in a quar­ter­ly earn­ings up­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.